Confo’s €30M growth plan

BioGeneration, Wellington lead series A for GPCR agonist company Confo

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round, announced on

Read the full 374 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE